Pharmaceuticals
Bora Group announce the rebranding of Yuta Health to Bora Health
TAIPEI, July 6, 2021 /PRNewswire/ -- Leading Taiwan-based contract development and manufacturing organization (CDMO) Bora Group today announced a name change for its subsidiary, currently Yuta Health, to Bora Health Inc. as part of an overall plan to integrate its distribution operations and b...
2021-07-06 13:31
3389
Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib in Clinical Studies in China
SAN FRANCISCO and SUZHOU, China, July 6, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...
2021-07-06 08:00
5639
South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology
DAEJEON, South Korea and CASTRES, France, July 6, 2021 /PRNewswire/ -- The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights toPierre Fabre to develop and commercialize a family of hum...
2021-07-06 07:00
5644
Octapharma's ongoing dedication to improving the lives of people with haemophilia and von Willebrand disease to be showcased at the ISTH 2021 Congress
LACHEN, Switzerland, July 5, 2021 /PRNewswire/ -- Octapharma announced today that new clinical and scientific findings encompassing their Haematology portfolio, including Nuwiq®, wilate®, octanate® and octanine®F, will be presented at the upcoming International Society on Thrombosis and Haemostas...
2021-07-05 19:30
3424
Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories
SHANGHAI, July 5, 2021 /PRNewswire/ -- Everest Medicines
2021-07-05 18:16
5170
Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China
SHANGHAI, BEIJING, HONG KONG, July 5, 2021 /PRNewswire/ -- Sperogenix (Shanghai ) MedTech Co., Ltd. ("Sperogenix"), a subsidiary of Sperogenix Therapeutics (platform company for development and commercialization of rare diseases medications inChina), has entered into an exclusive licensing agreeme...
2021-07-05 08:51
2433
New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP), Lispro (GL-LIS), and Glargine (GL-GLA) Presented at the American Diabetes Association's 81st Scientific Sessions
BEIJING and BRIDGEWATER, NJ., July 2, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), announced positive Phase 1 clinical trial results at the 81st Scientific Sessions of the American Diabetes Association (ADA),June 25th – 29...
2021-07-02 15:00
3734
Lipidor AB licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70
STOCKHOLM, Sweden, July 2, 2021 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that it has signed a licence agreement under which Lipidor grants RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, exclusive rights to re...
2021-07-02 05:32
2478
Ildong Pharmaceutical starts Phase 1 study of new diabetes therapy in Germany
SEOUL, South Korea, July 1, 2021 /PRNewswire/ -- A Phase 1 study on new drug candidate IDG16177 of novel oral treatment for type 2 diabetes, which is being developed by Ildong Pharmaceutical, is initiated inGermany. On June 28th (local time), Ildong Pharmaceutical obtained approval for the Phas...
2021-07-01 21:00
2666
Elliott Publishes Letter on GlaxoSmithKline
Elliott believes GSK has a substantial value creation opportunity – 45% upside in its share price – ahead of Consumer Health separation and greater beyond Despite its strengths, GSK has a poor record of operational execution and value creation, leading to scepticism about the Company's future, an...
2021-07-01 14:45
2195
Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines
Led by Viking Global Investors, the Series B round will be used to bring Antheia's first pharmaceutical compounds to market, expand its pipeline and scale production in global markets MENLO PARK, Calif., June 30, 2021 /PRNewswire/ -- Antheia, a synthetic biology company enabling next-generation ...
2021-06-30 20:00
2721
Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate
* Clover to procure CpG 1018 adjuvant from Dynavax for use in the commercial production of Clover's COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum) * Pending conditional regulatory approvals, Clover expects to commence product launch of SCB-2019 (CpG 1018/Alum) by the end of 2021 CHENGDU,...
2021-06-30 16:00
6144
Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover's COVID-19 Vaccine for the COVAX Facility
* Pending WHO EUL for its COVID-19 vaccine candidate, Clover is committed to providing 64 million doses in 2021 and Gavi has options for an additional 350 million doses in 2022 * Clover will receive a significant upfront payment, a payment upon positive Phase 2/3 data, potential payments upon...
2021-06-30 16:00
3161
Envirotainer Greets China Airlines as the latest airline to approve the new Releye® RLP container
STOCKHOLM, June 30, 2021 /PRNewswire/ -- Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, today announced that China Airlines has approved the Envirotainer Releye® RLP for usage on their aircrafts. With this approval, China Airlines ...
2021-06-30 14:48
2326
European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients
Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage 2 melanoma patients BRUSSELS and CASTRES, France, June 29, 2021 /PRNewswire/ -- European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre today announced a strategic part...
2021-06-29 20:13
2443
Medical Affairs Teams are Increasingly Turning to Patient-centric Analytics to Improve Clinical Outcomes
SANTA CLARA, Calif., June 29, 2021 /PRNewswire/ -- The shift to value-based care relies heavily on evidence-based medicine, and pharmaceutical companies play an important role in scientific communication across the healthcare ecosystem. Medical affairs experts interact with healthcare professiona...
2021-06-29 18:02
1562
Seegene unveils "MOBILE STATION," for on-site routine testing at public-use facilities and communities
* Seegene unveils "MOBILE STATION" at the Medlab Middle East 2021 * Mobile laboratory designed for mass testing at schools, airports, or communities, delivering test results within 3h 30min with the maximum testing capacity of 7,500 a day * The biotechnology firm to sign an MOU with G42 Heal...
2021-06-29 18:00
2300
RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study
Opaganib strongly inhibits Beta (South African) and Gamma (Brazilian) COVID-19 variants, further supporting its antiviral activity Opaganib's unique, orally-administered, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is also expected to maintain effect agai...
2021-06-28 19:00
12979
Qbiotics concludes successful $85 million capital raise
* Capital raise nets $85 million from Existing Shareholders, Existing Institutional Investors, and cornerstone investor TDM Growth Partners. * Funding to enable human clinical development of the Company's anticancer drug candidate tigilanol tiglate and its wound healing drug candidate EBC-1013...
2021-06-28 09:36
3500
CStone announces positive registrational study of GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer
* Key efficacy data for GAVRETO showed deep and durable anti-tumor activity in Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) * In March 2021, GAVRETO was approved by the National Medical Products Administration (NMPA) ofChina for the treatment of patie...
2021-06-28 08:05
6698
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 280 media titles]
2026-05-20 09:15Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
6234
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
6218
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
6021
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
5951
